Silver Book Fact

Prescription eye drops could delay or prevent half of glaucoma cases in African Americans.

Higginbotham, Eve J., Mae O. Gordon, Julie A. Beiser, Michael V. Drake, G. Richard Bennett, M. Roy Wilson, and Michael A. Kass. The Ocular Hypertension Treatment Study: Topical medication delays or prevents primary open-angle glaucoma in African American individuals. Archives of Ophthalmology. 2004; 122(6): 813-20. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=15197055&dopt=AbstractPlus

Reference

Title
The Ocular Hypertension Treatment Study: Topical medication delays or prevents primary open-angle glaucoma in African American individuals
Publication
Archives of Ophthalmology
Publication Date
2004
Authors
Higginbotham, Eve J., Mae O. Gordon, Julie A. Beiser, Michael V. Drake, G. Richard Bennett, M. Roy Wilson, and Michael A. Kass
Volume & Issue
Volume 122, Issue 6
Pages
813-20
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Lucentis to treat wet age-related macular degeneration (AMD)
    An FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)–ranibizumab (Lucentis)–maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25%…  
  • Screening and treatment for diabetic retinopathy in type 2 diabetes patients produces annual savings of 53,986 person-years of sight.  
  • Nearly 50% of diabetic retinopathy patients who received ranibizumab–an anti-VEGF drug–experienced substantial visual improvement after a year of injections  
  • Screening and treatment of diabetic retinopathy in type 2 diabetes patients produces annual savings of $247.9 million to the federal budget– in 1994 dollars.  
  • Intensive glucose control (3 or more daily insulin injections or continuous subcutaneous insulin infusion) reduced the mean risk of retinopathy progression by 54% in type 1 diabetes patients with minimal-to-moderate…